Alvotech
ALVO$1.29B
Small CapNASDAQBiotechnology🇺🇸North America1.0K employees
Drugs in Pipeline
7
Phase 3 Programs
7
Upcoming Catalysts
3
Next Catalyst
Aug 12, 2026
7wMarket Overview
Stock performance and key metrics
ALVO News
Catalyst Timeline
3 upcoming, 0 past
Drug Pipeline
Adalimumab
Plaque Psoriasis
AVT05 (proposed biosimilar to golimumab)
Rheumatoid Arthritis
AVT03
Osteoporosis, Postmenopausal
Stelara
Psoriasis
Adalimumab originator
Plaque Psoriasis
AVT06 (proposed aflibercept biosimilar)
Neovascular (Wet) AMD
AVT29 (proposed aflibercept HD biosimilar)
Diabetic Macular Edema
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Adalimumab | Phase 3 | Plaque Psoriasis | - | - |
AVT05 (proposed biosimilar to golimumab) | Phase 3 | Rheumatoid Arthritis | - | - |
AVT03 | Phase 3 | Osteoporosis, Postmenopausal | - | - |
Stelara | Phase 3 | Psoriasis | - | - |
Adalimumab originator | Phase 3 | Plaque Psoriasis | - | - |
AVT06 (proposed aflibercept biosimilar) | Phase 3 | Neovascular (Wet) AMD | - | - |
AVT29 (proposed aflibercept HD biosimilar) | Phase 3 | Diabetic Macular Edema | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply